Your session is about to expire
← Back to Search
Procedure
Trigger Point Injections for Myofascial Pain
Phase 2
Waitlist Available
Led By Mohab Ibrahim, Md., Ph.D
Research Sponsored by University of Arizona
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnosis of myofascial pain
Failed conservative therapy or unable to participate in physical therapy
Must not have
Serious mental illness that may not enable the patient to perceive pain changes
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 60 days
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
No Placebo-Only Group
Summary
This trial studies how different numbers of needle passes during trigger point injections affect pain relief in patients with chronic myofascial pain. The treatment involves injecting a numbing medicine into painful muscle areas and moving the needle in and out multiple times. The goal is to find out which method provides the best pain relief.
Who is the study for?
This trial is for English-speaking individuals with myofascial pain who haven't found relief through conservative treatments or can't do physical therapy. It's not suitable for those with serious mental illnesses that affect pain perception or conditions causing widespread pain.
What is being tested?
The study tests how many needle passes in trigger point injections (using lidocaine and bupivacaine) are best for relieving chronic muscle pain. Participants will be randomly assigned to receive either 2, 10, or 20 needle passes at a clinic in Tucson, Arizona.
What are the potential side effects?
Possible side effects from the injections may include temporary discomfort at the injection site, bruising, bleeding, allergic reactions to the anesthetics used (lidocaine and bupivacaine), and rarely nerve damage.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with muscle pain.
Select...
Physical therapy did not work for me or I cannot do it.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have a mental illness that affects my ability to feel changes in pain.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 60 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in pain intensity
Secondary study objectives
Change in Sleep patterns
Perceived Subjective Changes in the Ability to Work, Do Chores, and Exercise.
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Active Control
Group I: One to two needle passesActive Control1 Intervention
Receive 1-2 needle passes for needling at each trigger point
Group II: Ten needle passesActive Control1 Intervention
Receive 10 needle passes for needling at each trigger point
Group III: Twenty needle passesActive Control1 Intervention
Receive 20 needle passes for needling at each trigger point
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Trigger Point Injections (TPIs) with local anesthetics and needling are common treatments for Myofascial Pain Syndrome (MPS). TPIs involve injecting a local anesthetic into myofascial trigger points to numb the area, reduce pain, and interrupt the pain cycle.
Needling helps break up tight muscle bands and trigger points, promoting muscle relaxation and improved blood flow. These treatments are important for MPS patients as they directly target the source of pain, providing relief and improving muscle function.
Find a Location
Who is running the clinical trial?
University of ArizonaLead Sponsor
534 Previous Clinical Trials
159,234 Total Patients Enrolled
Mohab Ibrahim, Md., Ph.DPrincipal InvestigatorUniversity of Arizona
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have a history of conditions that cause widespread pain.I have a mental illness that affects my ability to feel changes in pain.I have been diagnosed with muscle pain.Physical therapy did not work for me or I cannot do it.
Research Study Groups:
This trial has the following groups:- Group 1: One to two needle passes
- Group 2: Ten needle passes
- Group 3: Twenty needle passes
Awards:
This trial has 3 awards, including:- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Myofascial Pain Syndrome Patient Testimony for trial: Trial Name: NCT04732507 — Phase 2
Share this study with friends
Copy Link
Messenger